Related Experiment Video

Updated: Mar 25, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

493

MicroRNAs and cancer resistance: A new molecular plot

F Fanini1, M Fabbri2

  • 1Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l. IRCCS, Unit of Gene Therapy, Meldola (FC), Italy.

Clinical Pharmacology and Therapeutics
|February 15, 2016
PubMed

Insights

Drug resistance causes cancer relapse, limiting chemotherapy efficacy. MicroRNAs (miRNAs) are implicated in this resistance, suggesting novel therapeutic strategies targeting these molecules to improve cancer treatment sensitivity.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cancer drug resistance is a primary cause of treatment failure and relapse.
  • MicroRNAs (miRNAs), short noncoding RNAs, are frequently altered in cancers and linked to drug resistance.
  • Current understanding of miRNA's role in drug resistance is incomplete, necessitating further research.

Purpose of the Study:

  • To review the latest discoveries on microRNAs involved in cancer therapy resistance.
  • To highlight the potential of targeting miRNAs to overcome drug resistance.

Main Methods:

  • Literature review of recent studies on miRNAs and cancer drug resistance.
  • Analysis of evidence linking miRNA dysregulation to acquired and intrinsic drug resistance.
  • Exploration of therapeutic strategies involving miRNA modulation (antagomiRs, mimics).

Main Results:

  • Growing evidence implicates miRNAs in the development of tumor cell drug resistance.
  • miRNA modulation offers a promising avenue for restoring sensitivity to chemotherapy.
  • Specific miRNAs can be targeted to potentially re-sensitize cancer cells to therapeutic agents.

Conclusions:

  • MicroRNAs play a significant role in cancer drug resistance.
  • Targeting miRNAs represents a novel therapeutic strategy to enhance chemotherapy effectiveness.
  • Further research into miRNA-mediated resistance mechanisms is crucial for developing innovative cancer treatments.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

9.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
MicroRNAs01:22

MicroRNAs

12.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K